跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
A-223
首页
药物
A-223
A-223
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Use of miR-223-3p as a cancer therapeutic and method for treating cancer using the same
申请人: UNIV FLORIDA
优先权: 2017
US
Isotope preparation method
申请人: ALGETA ASA
优先权: 2010
EP
MiR-223-3p for inhibiting growth and transfer of osteosarcoma
申请人: CHINESE PLA GENERAL HOSPITAL
优先权: 2018
CN
Isotope preparation method
申请人: ALGETA ASA
优先权: 2010
EP
US
3 件公开
Radioactive medical isotope Ra-223 stably-labeled rare earth nano diagnosis and treatment preparation as well as preparation method and application thereof
申请人: ZHONGKE RARE EARTH NANO TECH HEBEI CO LTD
优先权: 2024
CN
New application of miR-223
申请人: UNIV NANKAI
优先权: 2009
CN
COMPOSITION FOR PREVENTING OR TREATING LIVER DAMAGE COMPRISING MIR-223 AS ACTIVE INGREDIENT
申请人: ASAN FOUND
优先权: 2023
WO
Blue crab antibacterial peptide Scypasin 203-223 and application of blue crab antibacterial peptide Scypasin 203-223 in food preservation and fresh keeping
申请人: UNIV XIAMEN
优先权: 2024
CN
药物
反馈